BioSpace News Archive

Actions taken in response to approval of shareholder proposals presented at the Company’s 2019 Annual General Meeting

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), today announced that it will issue financial results for its fiscal year ended September 30, 2019 on Monday December 16, 2019.

Enochian Biosciences, a company focused on gene-modified cellular therapy in infectious disease and cancer, announces that important scientific findings reveal an innovative approach to potentially treat and cure Hepatitis B.

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2019, and highlighted recent corporate accomplishments.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304).

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development.

Genetic Technologies Limited is pleased to announce the full commissioning of its Australian Laboratory for the provisioning of its generation 3 breast cancer test with sales to commence in Q1, 2020.

Shoulder Innovations,, a leading innovator in the development of shoulder replacement systems, announced that they have received FDA clearance for their InSet Plus™ augmented glenoids for the InSet™ Total Shoulder System.

Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to commence a Phase 2 expansion cohort based on encouraging clinical activity and a well-tolerated safety profile observed to date in the ongoing Phase 1 dose escalation trial of SNDX-6352 in patients with chronic graft versus host disease (cGVHD).

Cantel Medical Corp. (NYSE: CMD) today announced financial results for its first quarter ended October 31, 2019.